Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellceutix Corporation will commence clinical trials of anti-cancer drug, Kevetrin at Harvard Cancer Center's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center following the Institutional Review Board (IRB) approval of clinical protocol amendment.
Subscribe to our email newsletter
The company expects the process of activation, recruitment, enrolling and first dosing to take nearly 3 weeks.
Cellceutix president and chief scientific officer Krishna Menon said institutions such as Dana-Farber and Beth Israel Deaconess are meticulous in their protocol.
”It is this level of excellence that compelled us to sponsor the trials at these clinical sites," Menon added.
Cellceutix chief executive officer Leo Ehrlich said many people have met Menon and him to discuss about Kevetrin and the rest of the Cellceutix pipeline.
”Our novel cancer drug candidate is garnering quite a lot of attention and we are confident that interest is going to continue to grow as the clinical trials progress," Ehrlich added.